Theravance Biopharma, Inc. Operating Lease Cost
Theravance Biopharma, Inc. (TBPH) reported Operating Lease Cost of $8.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-23
- Theravance Biopharma, Inc. operating lease, cost for the quarter ending 2019-12-31 was -$23.00K.
- Theravance Biopharma, Inc. operating lease, cost for the quarter ending 2019-09-30 was $2.75M.
- Theravance Biopharma, Inc. operating lease, cost for the quarter ending 2019-06-30 was $2.61M.
- Theravance Biopharma, Inc. operating lease, cost for the quarter ending 2019-03-31 was $2.78M.
- Theravance Biopharma, Inc. operating lease, cost for fiscal 2025 was $8.25M, a 3.15% decline from fiscal 2024.
- Theravance Biopharma, Inc. operating lease, cost for fiscal 2024 was $8.52M.
- Theravance Biopharma, Inc. operating lease, cost for fiscal 2022 was $8.31M, a 9.04% increase from fiscal 2021.
- Theravance Biopharma, Inc. operating lease, cost for fiscal 2021 was $7.63M, a 12.68% decline from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $8.25M 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $8.52M 10-K · filed 2026-03-23 | ||||
| 2022-12-31 | $8.31M 10-K · filed 2023-03-01 | ||||
| 2021-12-31 | $7.63M 10-K · filed 2023-03-01 | ||||
| 2020-12-31 | $8.73M 10-K · filed 2023-03-01 | ||||
| 2019-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.73M derived: sum of 2 quarters · filed 2022-02-28 | $5.34M derived: sum of 3 quarters · filed 2022-02-28 | $8.12M 10-K · filed 2022-02-28 | $10.13M 10-K · filed 2020-02-27 |
| 2019-09-30 | $2.75M 10-Q · filed 2019-11-08 | $5.36M derived: sum of 2 quarters · filed 2019-11-08 | $8.15M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $2.61M 10-Q · filed 2019-08-05 | $5.40M 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $2.78M 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $7.99M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |